Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase c...
Prof Jorge Cortes - Augusta University, Augusta, USA
OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid leukaemia ( Prof Jorge Cortes - Augusta University, Augusta, USA )
13 Jun 2020
VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myelo...
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myeloid leukaemia ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
13 Jun 2020
AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory mu...
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory multiple myeloma ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )
13 Jun 2020
Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )
13 Jun 2020
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
13 Jun 2020
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
13 Jun 2020
CANDOR updated results: KdD versus Kd in patients with RRMM according to prior l...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapy ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
13 Jun 2020
Patient reported outcomes for the CANDOR trial for multiple myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
Patient reported outcomes for the CANDOR trial for multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
13 Jun 2020
Reducing damage to swallowing muscles during radiotherapy for head and neck canc...
Prof Christopher Nutting - The Royal Marsden NHS Foundation Trust, London, UK
Reducing damage to swallowing muscles during radiotherapy for head and neck cancers ( Prof Christopher Nutting - The Royal Marsden NHS Foundation Trust, London, UK )
12 Jun 2020
Updated results from KEYNOTE-426 for metastatic kidney cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
Updated results from KEYNOTE-426 for metastatic kidney cancer ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )
12 Jun 2020
HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve p...
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
HCRN GU16-260: Nivolumab and salvage nivolumab   ipilimumab in treatment-naïve patients with advanced renal cell carcinoma ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )
12 Jun 2020
Comment: JAVELIN-100 for metastatic urothelial cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
Comment: JAVELIN-100 for metastatic urothelial cancer ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )
12 Jun 2020